

Title	Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence
Authors	O'Brien, Gary L.;Carrol, Donal;Mulcahy, Mark;Walshe, Valerie;Courtney, Garry;Byrne, Stephen
Publication date	2018-02-27
Original Citation	O'Brien, G. L., Carrol, D., Mulcahy, M., Walshe, V., Courtney, G. and Byrne, S. (2018) 'Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence', Generics and Biosimilars Initiative Journal (Gabi Journal), 7(1), pp. 14-21. doi:10.5639/gabij.2018.0701.004
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.5639/gabij.2018.0701.004
Rights	© 2018, Pro Pharma Communications International. All rights reserved. The original publication is available at www.gabi-journal.net
Download date	2025-04-24 09:40:19
Item downloaded from	https://hdl.handle.net/10468/6603



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Table 1 Areas under Investigation in the Irish Biosimilar Consultation Paper	
Prescribing and Interchangeability	By focusing on the remit of biological medicine prescribing, it is hoped that the low uptake of biosimilars in Ireland can be increased
International Biosimilar Medicines Policies	International policies are being examined to decide which policy, if any, could be implemented in the Irish context
Education and Supports	Educational programs and supports are being researched from the perspectives of the patient, healthcare professionals and pharmaceutical suppliers
Incentives and Disincentives	Incentives such as gain-sharing agreements and disincentives like patient co-payment systems are being analysed
Tendering and Pricing Policies	Internal and/or external referencing pricing arrangements as well as the various types of tendering processes used in different countries are being probed for their suitability in the Irish setting
Prevention of Inappropriate Business Practices	In addition to inappropriate business practices previously highlighted, exploration of such professional misconduct is being carried out